Eleven Biotherapeutics (EBIO) : Traders are bullish on Eleven Biotherapeutics (EBIO) as it has outperformed the S&P 500 by a margin of 17.75% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 15.74%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 16.45% in the last 1 week, and is up 25.7% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Eleven Biotherapeutics (NASDAQ:EBIO): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.64 and $2.52 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.71. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.69, notching a gain of 3.46% for the day. The total traded volume was 792,413 . The stock had closed at $2.60 on the previous day.
The stock has recorded a 20-day Moving Average of 20.49% and the 50-Day Moving Average is 43.55%. Eleven Biotherapeutics, Inc. is up 79.33% in the last 3-month period. Year-to-Date the stock performance stands at -10.63%.
Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye. The Company is conducting research and development programs directed at both diseases of the front of the eye, such as dry eye disease and allergic conjunctivitis, and diseases of the back of the eye, such as diabetic macular edema (DME) and uveitis. The Companys lead product candidate is EBI-005, a cure for dry eye disease and allergic conjunctivitis. Its preclinical product candidates include EBI-031, a cure for DME, and EBI-028, a cure for uveitis.